Oncologie

, Volume 14, Issue 9, pp 512–519

Nouvelles perspectives et biomarqueurs dans le diagnostic et la prise en charge des tumeurs gynécologiques

Mise au Point / Update

Résumé

Les tumeurs gynécologiques rassemblent un groupe hétérogène de lésions. Chaque organe du tractus génital féminin présente une pathologie tumorale avec une oncogenèse distincte. Nous rapportons ici les nouvelles avancées dans le domaine de la biologie moléculaire et de l’histogenèse des tumeurs épithéliales et des cordons sexuels de l’ovaire et des tumeurs épithéliales et mésenchymateuses utérines. Ces nouvelles découvertes scientifiques ont permis la mise en place de biomarqueurs tels que les marqueurs immunohistochimiques et tests moléculaires, qui apportent une aide considérable aux pathologistes dans leur pratique au quotidien. Ils permettent le diagnostic des différents sous-types histologiques de tumeurs gynécologiques en complément de l’examen morphologique au microscope. Enfin, ces nouveaux biomarqueurs ouvrent la voie à la mise en place de nouvelles thérapies ciblées dans un futur proche.

Mots clés

Carcinome ovarien FOXL2 FISH Sarcome utérin Carcinome endométrial 

New perspectives and biomarkers in the diagnosis and management of gynecological tumors

Abstract

Gynecological tumors comprise a heterogeneous group of lesions, with each organ of female genital tract displaying distinct tumor pathology and oncogenesis. We report herein the newly described molecular abnormalities in carcinomas and sex cord-stromal tumors of the ovary as well as in epithelial and mesenchymal uterine neoplasms. The biomarkers such as immunohistochemical antibodies and molecular testing help the pathologists in their every day practice. Our better understanding of the molecular bases of gynecological tumors represents the first step in the development of targeted therapies in the near future.

Keywords

Ovarian carcinoma FOXL2 FISH Uterin sarcoma Endometrial carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79: 1581–1586PubMedCrossRefGoogle Scholar
  2. 2.
    Cuatrecasas M, Catasus L, Palacios J, Prat J (2009) Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol 33: 556–567PubMedCrossRefGoogle Scholar
  3. 3.
    D’Angelo E, Mozos A, Nakayama D, et al. (2011) Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol 24: 1360–1367PubMedCrossRefGoogle Scholar
  4. 4.
    Geyer JT, López-García MA, Sánchez-Estevez C, et al. (2009) Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 33: 1157–1163PubMedCrossRefGoogle Scholar
  5. 5.
    Gibault L, Pérot G, Chibon F, et al. (2011) New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 223: 64–71PubMedCrossRefGoogle Scholar
  6. 6.
    Gibault L, Ferreira C, Pérot G, et al. (2012) From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas. Mod Pathol 25: 197–211PubMedGoogle Scholar
  7. 7.
    Grossmann AH, Layfield LJ, Randall RL (2012) Classification, molecular characterization and the significance of PTEN alteration in leiomyosarcoma. Sarcoma 2012: 1–8CrossRefGoogle Scholar
  8. 8.
    Gurin CC, Federici MG, Kang L, Boyd J (1999) Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 59: 462–466PubMedGoogle Scholar
  9. 9.
    Hayes MP, Wang H, Espinal-Witter R, et al. (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932–5935PubMedCrossRefGoogle Scholar
  10. 10.
    Hernando E, Charytonowicz E, Dudas ME, et al. (2007) The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13: 748–753PubMedCrossRefGoogle Scholar
  11. 11.
    Ito M, Barys L, O’Reilly T, et al. (2011) Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 17: 416–426PubMedCrossRefGoogle Scholar
  12. 12.
    Jia L, Liu Y, Yi X, et al. (2008) Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 14: 2263–2269PubMedCrossRefGoogle Scholar
  13. 13.
    Kindelberger DW, Lee Y, Miron A, et al. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31: 161–169PubMedCrossRefGoogle Scholar
  14. 14.
    Kuo KT, Mao TL, Jones S, et al. (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597–1601PubMedCrossRefGoogle Scholar
  15. 15.
    Lee CH, Mariño-Enriquez A, Ou W, et al. (2012) The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 36: 641–653PubMedCrossRefGoogle Scholar
  16. 16.
    Lee CH, Ou WB, Mariño-Enriquez A, et al. (2012) 14-3-3 fusion oncogenes in highgrade endometrial stromal sarcoma. Proc Natl Acad Sci USA 109: 929–934PubMedCrossRefGoogle Scholar
  17. 17.
    Machin P, Catasus L, Pons C, et al. (2002) CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 33: 206–212PubMedCrossRefGoogle Scholar
  18. 18.
    McAlpine JN, Wiegand KC, Vang R, et al. (2009) HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9: 433PubMedCrossRefGoogle Scholar
  19. 19.
    Mäkinen N, Mehine M, Tolvanen J, et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334: 252–255PubMedCrossRefGoogle Scholar
  20. 20.
    Mutter GL, Lin MC, Fitzgerald JT, et al. (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924–930PubMedCrossRefGoogle Scholar
  21. 21.
    Pérot G, Croce S, Ribeiro A, et al. (2012) MED12 alterations in both human benign and malignant uterine soft tissue tumors. Plos One (sous presse)Google Scholar
  22. 22.
    Pérot G, Chibon F, Montero A, et al. (2010) Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol 177: 2080–2090PubMedCrossRefGoogle Scholar
  23. 23.
    Sadhna D, Rodriguez ME, Shen Q, et al. (2011) Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. Int J Clin Exp Pathol 4: 134–136Google Scholar
  24. 24.
    Sato N, Tsunoda H, Nishida M, et al. (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60: 7052–7056PubMedGoogle Scholar
  25. 25.
    Schmeler KM, Sun CC, Bodurka DC, et al. (2008) Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108: 510–514PubMedCrossRefGoogle Scholar
  26. 26.
    Shah SP, Köbel M, Senz J, et al. (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360: 2719–2729PubMedCrossRefGoogle Scholar
  27. 27.
    Singer G, Stöhr R, Cope L, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and lowand high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218–224PubMedCrossRefGoogle Scholar
  28. 28.
    Tung CS, Mok SC, Tsang YT, et al. (2009) PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22: 1243–1250PubMedCrossRefGoogle Scholar
  29. 29.
    Wiegand KC, Shah SP, Al-Agha OM, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532–1543PubMedCrossRefGoogle Scholar
  30. 30.
    Xing D, Scangas G, Nitta M, et al. (2009) A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 69: 8231–8235PubMedCrossRefGoogle Scholar
  31. 31.
    Yamamoto S, Tsuda H, Aida S, et al. (2007) Immunohistochemical detection of hepatocyte nuclear factor 1 beta in ovarian and endometrial clearcell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 38: 1074–1080PubMedCrossRefGoogle Scholar
  32. 32.
    Zheng W, Yi X, Fadare O, et al. (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32: 304–315PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2012

Authors and Affiliations

  1. 1.Service de pathologiehôpital de la Croix-Rousse, centre de biologie et pathologie Nordcedex 04France
  2. 2.Département de pathologieinstitut BergoniéBordeaux cedexFrance

Personalised recommendations